Redcare Pharmacy NV (ETR:RDC)
Germany
· Delayed Price · Currency is EUR | Market Cap | 974.20M |
| Revenue (ttm) | 2.94B |
| Net Income (ttm) | -37.70M |
| Shares Out | 20.11M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,713 |
| Average Volume | 166,137 |
| Open | 47.84 |
| Previous Close | 48.44 |
| Day's Range | 47.82 - 49.01 |
| 52-Week Range | 30.20 - 136.50 |
| Beta | 1.32 |
| RSI | 57.20 |
| Earnings Date | May 6, 2026 |
About Redcare Pharmacy NV
Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023. Redcare Pharmacy NV was founded in 2001 and is based in Sevenum, the Netherlands. [Read more]
Financial Performance
In 2025, Redcare Pharmacy NV's revenue was 2.94 billion, an increase of 24.06% compared to the previous year's 2.37 billion. Losses were -37.70 million, -17.14% less than in 2024.
Financial StatementsNews
Redcare Pharmacy NV Earnings Call Transcript: Q4 2025
Full-year revenues rose 24% to EUR 2.9 billion, driven by strong Rx growth and logistics expansion. 2026 guidance targets 13%-15% sales growth, Rx Germany revenues above EUR 670 million, and an adjusted EBITDA margin of at least 2.5%.
German online drug retailer Redcare Pharmacy names Hendrik Krampe as CFO
German online drug retailer Redcare Pharmacy on Monday named Hendrik Krampe as its chief financial officer, effective December 1.
Redcare Pharmacy NV Earnings Call Transcript: Q3 2025
Sales grew 27% year-over-year with strong gains in both Rx and non-Rx segments, and adjusted EBITDA margin reached 2.1% year-to-date. Cash flow and liquidity remain robust, supporting ongoing investments in logistics and automation, while full-year guidance is reiterated.
Redcare Pharmacy NV Earnings Call Transcript: Q2 2025
Sales grew 27% year-over-year with record adjusted EBITDA and strong Rx momentum, especially in Germany. Guidance for over 25% sales growth and 2–2.5% EBITDA margin is confirmed, supported by regulatory wins and robust cash flow.
Redcare Pharmacy NV Earnings Call Transcript: Q1 2025
Q1 2025 saw 28% sales growth to €717M, driven by RX and ERX, with positive EBITDA and strong customer gains. Guidance for 2025 is reiterated, with margin improvement expected as seasonality and efficiency gains take effect.
Redcare Pharmacy NV Earnings Call Transcript: Q4 2024
Exceptional 2024 growth was driven by e-Rx adoption in Germany, market leadership in multiple countries, and strong customer metrics. Sales rose 32% to nearly EUR 2.4 billion, with Rx up 64% and adjusted EBITDA at EUR 33 million. 2025 guidance targets >25% sales growth and margin improvement.
CTP Builds 30,000 sqm of Distribution Space for Redcare Pharmacy, Europe's Leading Online Pharmacy
AMSTERDAM--(BUSINESS WIRE)--Regulatory News: CTP, Europe's largest listed developer, owner, and manager of industrial and logistics properties by gross lettable area (GLA), today began the constructio...
Redcare Pharmacy NV Earnings Call Transcript: Q3 2024
Sales grew 34% year-over-year to €1.7 billion, with strong eRx momentum in Germany and non-Rx growth at 20%. Adjusted EBITDA margin was 2.3% YTD, and market share in German eRx rose to 0.66% in October. Full-year sales guidance is €2.35–2.5 billion.
Redcare Pharmacy NV Transcript: Trading Update
Q3 saw 21% organic sales growth and a surge in German Rx sales, driven by strong eRx adoption and high repeat order rates. Full-year sales guidance was raised, while EBITDA margin guidance was narrowed due to increased Rx marketing investments. Management remains confident in long-term growth and profitability.
Redcare Pharmacy NV Earnings Call Transcript: Q1 2024
Redcare Pharmacy NV Earnings Call Transcript: Q4 2023
Redcare Pharmacy aims for higher 2024 sales after positive annual core earnings
Redcare Pharmacy on Tuesday forecast higher sales for 2024 after the online pharmacy operator posted upbeat adjusted annual core earnings, supported by a growing number of prescription sales.